Search

Your search keyword '"CLERICO, M"' showing total 50 results

Search Constraints

Start Over You searched for: Author "CLERICO, M" Remove constraint Author: "CLERICO, M" Topic business.industry Remove constraint Topic: business.industry
50 results on '"CLERICO, M"'

Search Results

1. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

2. The Italian multiple sclerosis register

3. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

4. Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort

5. Oral Prolonged-Release Oxycodone-Naloxone: Analgesic Response, Safety Profile, and Factors Influencing the Response in Patients With Advanced Cancer

6. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

7. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study

8. Breast cancer 'tailored follow-up' in Italian oncology units: a web-based survey

9. THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS

10. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

11. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

12. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial

13. Antiemetic Activity of Oral Lorazepam in Addition to Methylprednisolone and Metoclopramide in the Prophylactic Treatment of Vomiting Induced by Cisplatin. A Double-Blind, Placebo-Controlled Study with Crossover Design

14. Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b

15. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab

16. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?

17. Combination chemotherapy with carboplatin and methotrexate in the treatment of advanced urothelial carcinoma. A phase II study

18. Phase II trial of weekly 4-epi-doxorubicin (epirubicin) in squamous cell carcinoma of the head and neck

19. Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting

20. Phase II trial of VP16–213 in squamous cell carcinoma of the head and neck

21. Disability assessment using Google Maps

22. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

23. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail

24. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

25. Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis

26. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

27. A real‐world study of alemtuzumab in a cohort of Italian patients

28. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment

29. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers

30. Source of medical information and behavioral seeking patterns in patients affected with Friedreich’s ataxia and their caregivers: a survey study

31. Digital therapeutics in neurology

32. Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic

33. Stroke and digital technology: a wake-up call from COVID-19 pandemic

34. Digital work engagement among Italian neurologists

35. The Use of Social Media and Digital Devices Among Italian Neurologists

36. Sex effects across the lifespan in women with multiple sclerosis

37. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

38. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

39. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

40. Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a

41. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

42. Right phrenic nerve palsy following transcatheter radiofrequency current atrial fibrillation ablation: Case report

43. Early diagnosis of progressive multifocal leucoencephalopathy: Longitudinal lesion evolution

44. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study

45. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

46. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

47. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study

48. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study

49. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study

50. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)

Catalog

Books, media, physical & digital resources